Point-of-care Pharmacogenomic Testing to Optimize Isoniazid Dosing for Tuberculosis Prevention
Condition(s):Tuberculosis Infection; Isoniazid Adverse ReactionLast Updated:December 11, 2023Recruiting
Hide Studies Not Open or Pending
Condition(s):Tuberculosis Infection; Isoniazid Adverse ReactionLast Updated:December 11, 2023Recruiting
Condition(s):TuberculosisLast Updated:January 25, 2022Unknown status
Condition(s):Silicosis TuberculosisLast Updated:April 5, 2019Unknown status
Condition(s):HIV Seropositivity; Pregnancy; Tuberculosis InfectionLast Updated:March 18, 2024Recruiting
Condition(s):Tuberculosis; HIV InfectionsLast Updated:February 6, 2014Completed
Condition(s):Tuberculosis; Drug-Induced Liver Injury; Adverse Drug EventLast Updated:February 28, 2020Completed
Condition(s):HIVLast Updated:June 21, 2017Unknown status
Condition(s):HepatotoxicityLast Updated:March 17, 2014Unknown status
Condition(s):Infertility, Female; Recurrent Implantation Failure; Genital Tuberculoses, Female; Genital Tuberculosis, LatentLast Updated:August 27, 2020Unknown status
Condition(s):Pulmonary TuberculosisLast Updated:February 28, 2011Terminated
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.